Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies

This trial is to evaluate the efficacy of Gemcitabine-Cisplatin (GC) plus Envafolimab neoadjuvant therapy in the patients at high risk of recurrence. Primary endpoint: Major Pathologic Response (MPR). It will also learn about the safety of drug including Gemcitabine-Cisplatin (GC) plus Envafolimab as a neoadjuvant therapy in this trial.

NCT Number	NCT07599995
Lead Sponsor	Sir Run Run Shaw Hospital
Conditions	Biliary Tract Cancer
Enrollment	34 participants
Start Date	2026-05-30
Primary Completion	2028-03-30 (estimated)
Study Completion	2030-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-20